RNA N6‐methyladenosine methyltransferase‐like 3 promotes liver cancer progression through YTHDF2‐dependent posttranscriptional silencing of SOCS2

  • Mengnuo Chen
    State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing Faculty of Medicine,University of Hong Kong,Hong Kong
  • Lai Wei
    State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing Faculty of Medicine,University of Hong Kong,Hong Kong
  • Cheuk‐Ting Law
    State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing Faculty of Medicine,University of Hong Kong,Hong Kong
  • Felice Ho‐Ching Tsang
    State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing Faculty of Medicine,University of Hong Kong,Hong Kong
  • Jialing Shen
    State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing Faculty of Medicine,University of Hong Kong,Hong Kong
  • Carol Lai‐Hung Cheng
    State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing Faculty of Medicine,University of Hong Kong,Hong Kong
  • Long‐Hin Tsang
    State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing Faculty of Medicine,University of Hong Kong,Hong Kong
  • Daniel Wai‐Hung Ho
    State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing Faculty of Medicine,University of Hong Kong,Hong Kong
  • David Kung‐Chun Chiu
    State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing Faculty of Medicine,University of Hong Kong,Hong Kong
  • Joyce Man‐Fong Lee
    State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing Faculty of Medicine,University of Hong Kong,Hong Kong
  • Carmen Chak‐Lui Wong
    State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing Faculty of Medicine,University of Hong Kong,Hong Kong
  • Irene Oi‐Lin Ng
    State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing Faculty of Medicine,University of Hong Kong,Hong Kong
  • Chun‐Ming Wong
    State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing Faculty of Medicine,University of Hong Kong,Hong Kong

書誌事項

公開日
2018-04-19
権利情報
  • http://doi.wiley.com/10.1002/tdm_license_1.1
  • http://onlinelibrary.wiley.com/termsAndConditions#vor
DOI
  • 10.1002/hep.29683
公開者
Ovid Technologies (Wolters Kluwer Health)

この論文をさがす

説明

<jats:p>Epigenetic alterations have contributed greatly to human carcinogenesis. Conventional epigenetic studies have predominantly focused on DNA methylation, histone modifications, and chromatin remodeling. Recently, diverse and reversible chemical modifications of RNAs have emerged as a new layer of epigenetic regulation. N6‐methyladenosine (m6A) is the most abundant chemical modification of eukaryotic messenger RNA (mRNA) and is important for the regulation of mRNA stability, splicing, and translation. Using transcriptome sequencing, we discovered that methyltransferase‐like 3 (METTL3), a major RNA N6‐adenosine methyltransferase, was significantly up‐regulated in human hepatocellular carcinoma (HCC) and multiple solid tumors. Clinically, overexpression of METTL3 is associated with poor prognosis of patients with HCC. Functionally, we proved that knockdown of METTL3 drastically reduced HCC cell proliferation, migration, and colony formation <jats:italic toggle="yes">in vitro</jats:italic>. Knockout of METTL3 remarkably suppressed HCC tumorigenicity and lung metastasis <jats:italic toggle="yes">in vivo</jats:italic>. On the other hand, using the CRISPR/dCas9‐VP64 activation system, we demonstrated that overexpression of METTL3 significantly promoted HCC growth both <jats:italic toggle="yes">in vitro</jats:italic> and <jats:italic toggle="yes">in vivo</jats:italic>. Through transcriptome sequencing, m6A sequencing, and m6A methylated RNA immuno‐precipitation quantitative reverse‐transcription polymerase chain reaction, we identified suppressor of cytokine signaling 2 (SOCS2) as a target of METTL3‐mediated m6A modification. Knockdown of METTL3 substantially abolished SOCS2 mRNA m6A modification and augmented SOCS2 mRNA expression. We also showed that m6A‐mediated SOCS2 mRNA degradation relied on the m6A reader protein YTHDF2‐dependent pathway. <jats:italic toggle="yes">Conclusion</jats:italic>: METTL3 is frequently up‐regulated in human HCC and contributes to HCC progression. METTL3 represses SOCS2 expression in HCC through an m6A‐YTHDF2‐dependent mechanism. Our findings suggest an important mechanism of epigenetic alteration in liver carcinogenesis. (H<jats:sc>epatology</jats:sc> 2018;67:2254‐2270).</jats:p>

収録刊行物

  • Hepatology

    Hepatology 67 (6), 2254-2270, 2018-04-19

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (10)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ